WuXi Biologics (Cayman) Inc 2018 AR2
The report highlights WuXi Biologics' strong performance in 2018, with revenue increasing by 56.6% year-on-year to RMB2,534.5 million and the number of integrated projects reaching 205. The company launched global capacity expansion plans in the U.S., Ireland, China, and Singapore, aiming for a total capacity of over 220,000 liters. Notably, its cGMP manufacturing facilities in Wuxi were approved by both the U.S. FDA and the EMA, making it the first biologics company in China to achieve this dual approval. Additionally, WuXi Biologics successfully launched its proprietary WuXiBody, WuXia, and WuXiUP technology platforms to accelerate biologics discovery and development.
Company: WuXi Biologics (Cayman) Inc
Sector: Health Care
Country: China
Year: 2018
Type: AR2
Pages: 259
WuXi Biologics (Cayman) Inc
Annual Report
The report highlights WuXi Biologics' strong performance in 2018, with revenue increasing by 56.6% year-on-year to RMB2,534.5 million and the number of integrated projects reaching 205. The company launched global capacity expansion plans in the U.S., Ireland, China, and Singapore, aiming for a total capacity of over 220,000 liters. Notably, its cGMP manufacturing facilities in Wuxi were approved by both the U.S. FDA and the EMA, making it the first biologics company in China to achieve this dual approval. Additionally, WuXi Biologics successfully launched its proprietary WuXiBody, WuXia, and WuXiUP technology platforms to accelerate biologics discovery and development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Workplace Fatalities
Employees